RxDoctor Payments DataLook up a doctor →

Sandra Gawchik, DO

Allergy & Immunology · Upland, PANPI 1578608204

Payments from drug & device makers

$390,213in general payments, 2019–2025

Across 1,330 payments — averaging $293.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$176K
  • Regeneron Healthcare Solutions, Inc.$72K
  • Sanofi$34K
  • Genentech USA, Inc.$21K
  • Regeneron$16K
  • Novartis$16K
  • plus $56K from 34 others

What the payments were for

  • Consulting fees$99,87926%
  • Speaking & faculty fees$222,61757%
  • Travel & lodging$30,5678%
  • Food & beverage$36,3439%
  • Education$7110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$390,213 in reported general payments places this provider in the 95th percentile of 175 allergy & immunology providers in Pennsylvania.

See all allergy & immunology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$81,120
Medicare patients
274
Services billed
2,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab32$130,201
Dupixent SyringeDupilumab35$130,049
TezspireTezepelumab-Ekko21$119,712
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5013$91,911
RinvoqUpadacitinib12$71,309
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$28,990
Breo ElliptaFluticasone/Vilanterol44$28,019
Spiriva RespimatTiotropium Bromide37$25,988
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,121
Arnuity ElliptaFluticasone Furoate39$15,299
SymbicortBudesonide/Formoterol Fumarate45$14,611
Qvar RedihalerBeclomethasone Dipropionate39$11,748
Advair HfaFluticasone Propion/Salmeterol22$10,747
XhanceFluticasone Propionate12$7,662
DuleraMometasone/Formoterol17$7,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$176,375$163,312102 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$962$91,91113 claims
AbbVieRinvoq$6,680$71,30912 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$2,022$59,439101 claims
Boehringer IngelheimSpiriva Respimat$230$25,98837 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Acyclovir$46$11,86851 claims
Optinose US, Inc.Xhance$4,544$7,66212 claims
MerckDulera$4,664$7,29717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 allergy & immunology providers in Pennsylvania.

Other allergy & immunology in Upland

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →